Clinical profile of eprosartan

Cardiovascular Drugs and Therapy

Volumn 16, Issue 6, 2002, Pages 543-549

  Puig, Juan García ^a,b   López, María A Martínez ^a   Bueso, Teresa Sancho ^a   Bernardino, José I ^a   Jiménez, Rosa Torres ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Autonomic function; Efficacy; Eprosartan; Essential hypertension; Safety; Uric acid

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; URIC ACID;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; HEADACHE; HUMAN; HYPERTENSION; INJURY; KIDNEY BLOOD FLOW; MYALGIA; PHARYNGITIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINITIS; SINUSITIS; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; VASOCONSTRICTION; VERTIGO; VIRUS INFECTION;

ACRYLATES; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; IMIDAZOLES; RENIN-ANGIOTENSIN SYSTEM; THIOPHENES; TREATMENT OUTCOME;

EID: 0242416636     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022915220753     Document Type: Review

References (35)

1. Mimran A, Ribstein J. Angiotensin receptor blockers: Pharmacology and clinical significance. J Am Soc Nephrol 1999;10(Suppl 12):S273-S277.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-2446.
3. World Health Organization-International Society of Hypertension guidelines for the management of hypertension: Guidelines subcommittee. J Hypertens 1999;17:151-185.
4. de Abajo F, Lopo CR. Converting enzyme inhibitors in the treatment of chronic heart insufficiency: A meta-analysis of controlled clinical trials with placebo. Med Clin 1988;91:249-255.
5. Carg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA 1995;273:1450-1456.
6. Pfeffer MA. ACE inhibition in acute myocardial infarction. New Engl J Med 1995;332:118-120.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. New Engl J Med 1993;339:1456-1462.
8. Jafar TH, Schimd CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
9. The Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitot, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. New Engl J Med 2000;342:145-153.
10. Simon SS, Black HR, Moser M, Berland WE. Cough and ACE inhibitors. Arch Intern Med 1992;152:1698-1700.
11. Bakris GL, Weir MR. Angiotensin-coverting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000;160:685-693.
12. Gavras HP. Issues in hypertension: Drug tolerability and special populations. Am J Hypertens 2001;14:231S-236S.
13. Oparil S. Pharmacological differences among angiotensin II receptor blockers. Am J Hypertens 2000;13:18S-24S.
14. Conlin PR, Spence JD, Williams B, Ribeiro AB, Benedict C, Bunt AMG. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens 2000;13:418-426.
15. Balt JC, Mathy MJ, Pfaffendorf M, Zwieten PA. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: Comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 2001;19:2241-2250.
16. Hedner T, Himmelmann A. Eprosartan Multinational Study Group. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens 1999;17:129-136.
17. Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Clin Ther 1999;21:442-453.
18. White WB, Anis Anwar Y, Sica DA. Once daily effects of the angiotensin receptor blocker eprosartan on 24-hour blood pressure in patients with systemic hypertension. Am J Hypertens 1995;12(4 pt 2):27A (abstract).
19. Oparil S. Eprosartan versus enalapril in hypertensive patients with angiotensin-converting enzyme inhibitor-induced cough. Curr Ther Res 1999;60:1-14.
20. Puig JG, Mateos F, Buño A, Ortega R, Rodríguez F, Dal-Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-1039.
21. Sega R. Efficacy and safety of eprosartan in severe hypertension. Blood Press 1999;8:114-121.
22. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double blind, multicentre study. Curr Med Res Opin 1999;15:15-24.
23. Sachse A, Verboom CN, Jager B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002;16(3):169-176.
24. Levine B, Eprosartan Multinational Study Group. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: Subgroup analysis of a 26-week, double blind, multicentre study. Curr Med Res Opin 1999;15:25-32.
25. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double blind, multicentre study. Curr Med Res Opin 1999;15:9-14.
26. Staessen JA, Gasowski J, Wang JL, et al. Risk of untreated and treated isolated systolic hyertension in the elderly: Meta-analysis of outcome trials. Lancet 2000;35:1038-1042.
27. Ruilope L, Jäger B, Richard B. Eprosartan versus enalapril in elderly patients with hypertension: A double-blind, randomized trial. Blood Press 2001:10:223-229.
28. Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy 1999;19(Pt 2):102-107.
29. Physicians' Desk Reference (PDR). Eprosartan. 2002.
30. Martin DE, De Cherney GS, Ilson BE. Eprosartan, an angiotensin II AT1 receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. J Clin Pharmacol 1997;37:155-159.
31. Ilson BE, Martin DE, Boike SC, et al. A dose response study to assess the renal hemodynamic vascular and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy man. Clin Pharm Ther 1997;63(Suppl):471-481.
32. Hollenberg NK. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. Curr Hypertens Reports 2001;3(Suppl I):S25-S28.
33. Price DA, De'Oliveira JM, Fisher NDL, Hollenberg NK. Renal hemodynamic response to an angiotensin II receptor antagonist, eprosartan, in healthy men. Hypertension 1997;30:240-246.
34. Ilson BE, Martin DE, Boike SC, Jorkasky DK. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998;38:437-441.
35. Plosker GL, Foster RH. Eprosartan: A review of its use in the management of hypertension. Drugs 2000;60:177-201.